Q4 2025 QuidelOrtho Corp Earnings Call Transcript
Key Points
- QuidelOrtho Corp (QDEL) achieved $140 million in cost savings and expanded adjusted EBITDA margins to the low 20s.
- The Labs business reported strong growth of 7% in Q4, driven by clinical chemistry.
- For the full year, QuidelOrtho Corp (QDEL) achieved its 2025 financial guidance with $2.73 billion in revenue.
- Operating expenses decreased by 5% due to company-wide cost savings initiatives.
- FDA clearance was received for the high sensitivity troponin assay on the virus platform, with US shipments expected soon.
- Respiratory revenue declined by 14% in Q4 and 20% for the full year due to lower COVID-19 testing.
- Adjusted gross profit margin decreased by 190 basis points in Q4 due to tariffs, higher replacements, and product mix.
- Free cash flow conversion fell short of the 25% target, primarily due to ERP system issues and late sales.
- The company recorded a significant non-cash goodwill charge in Q3, impacting GAAP results.
- Net debt to adjusted EBITDA ratio was 4.2 times, above the target due to cash collection timing issues.
Good morning or good afternoon. Welcome to the QuidelOrtho fourth quarter and full-year 2025 financial results conference call and webcast. (Operator Instructions) Please note this call is being recorded. An audio replay of the conference call will be available on the company's website shortly after this call.
I would now like to turn the call over to Juliet Cunningham, Vice President of Investor Relations.
Thank you. Good afternoon, everyone. Thanks for joining us. With me today are Brian Blaser, President and Chief Executive Officer; Jonathan Siegrist, Chief Technology Officer; and Joe Busy, Chief Financial Officer. This conference call is being simultaneously webcast on the Investor Relations page of our website.
To assist in the presentation, we also posted supplemental information on our IR page that will be referenced throughout this call. This conference call and supplemental information contains forward-looking statements which are made as of today, February 11,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
